Although anti-SIRPA antibodies have been used previously as therapeutics against cancers in preclinical models, including a mouse neuroblastoma model [40,41,81], a comparison between the therapeutic efficacy of anti-SIRPA F(ab’)2 and the intact anti-SIRPA antibody has not been explored. This evidence concerns the gene SIRPA and cancer.